Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use …

Abstract

The present disclosure is directed to dual specific antibodies, which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.